Xizang Weixinkang Pharmaceutical Co., Ltd. Class A 603676

SSE · China · Health Technology

CNY 9.09+0.12 (+1.34%)

Market closed· Sep 30, 2026, 7:00 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Xizang Weixinkang Pharmaceutical Co., Ltd. Class A 603676

SSE · China · Health Technology

CNY 9.09+0.12 (+1.34%)

Market closed· Sep 30, 2026, 7:00 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-14.81% · 6MFull-screen chart

Open CNY 8.96High CNY 9.14Low CNY 8.94Close CNY 9.09Volume 1.49M

Sep 30, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: CNY 8.97
Day range: CNY 8.94 – CNY 9.14
52-week range: CNY 7.82 – CNY 12.08
Volume: 1.49M
Market cap: CNY 3.96B
P/E (TTM): 20.2
Dividend yield (annualized): 3.60%
Next earnings date: 2026-10-30
Avg. volume (1Y): 2.15M

Performance

1 week

+1.68%

1 month

-0.87%

3 months

+5.94%

6 months

-12.98%

Year to date

-14.58%

1 year

-19.39%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: China
Exchange: SSE
Shares outstanding: 432.33M
Employees: 763
ISIN: CNE100002QQ3
Beta: 0.44

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceOct 06, 2025

Undiscovered Gems In Asia Featuring 3 Promising Small Cap Stocks

As global markets navigate a complex landscape characterized by fluctuating economic indicators and shifting investor sentiment, small-cap stocks in Asia present intriguing opportunities amid broader market dynamics. With the Russell 2000 Index outperforming the S&P 500 due to expectations of lower interest rates, investors may find value in exploring smaller companies that are well-positioned to benefit from regional economic trends and sector-specific growth drivers.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.